Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus PENBRITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus PENBRITIN.
AMPICILLIN AND SULBACTAM vs PENBRITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and preventing peptidoglycan cross-linking, leading to cell lysis.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
0.5-1 hour in normal renal function; extended to 2-6 hours in renal impairment. Hemodialysis shortens half-life.
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Renal: ~75-90% unchanged via glomerular filtration and tubular secretion. Biliary: ~10% in feces. Minor hepatic metabolism to penicilloic acid.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic